This scanning electron microscope image shows SARS-CoV-2, the virus that causes Covid-19, (round blue objects) emerging from the surface of cells cultured in the lab. SARS-CoV-2, also known as 2019-nCoV, is the virus that causes Covid-19. The virus shown was isolated from a patient in the U.S. Image by the US NIAID (CC BY 2.0)
First published by GroundUp
Are you wondering why you have to wait a few days for the results of the Covid-19 test? One reason is that laboratory technicians must take pains to avoid getting it wrong what are called false negatives, and less often, false positives.
The other reason is that the techniques they use are done in a specialised laboratory, working with very small, precise quantities of what are known as reagents.
The first step is to take a swab from you as shown in this video from the New England Journal of Medicine (the worlds leading medical journal):
It may be a little uncomfortable, but grin and bear it; its for your own good.
You could also provide a sputum sample from your lower respiratory tract if you have a cough. A health worker will decide based on your symptoms, and the guidelines issued by the National Institute of Communicable Diseases (NICD), which route to take.
Looking for the virus
Lab technicians need the swab to check if you have the virus. They do this using a diagnostic test called a real-time reverse-transcription polymerase chain reaction (rRT-PCR) test. To do a PCR diagnostic test, a laboratory technician isolates the genetic material of the virus from the sample you have provided. The PCR technique is well-developed and there is plenty of information about it online.
A virus is a small infectious agent that multiplies in living cells. Viruses contain nucleic acids, which are the building blocks of living organisms. DNA and RNA are the primary nucleic acids. Some viruses may contain single-stranded nucleic acids, others may contain double-stranded nucleic acids. A genome is the complete set of hereditary material in an organism. Some viruses have RNA genomes, while other viruses have DNA genomes. The genomes of some RNA viruses can be translated directly into viral proteins and they serve as a template for genome replication. They are described as positive-sense.
The coronavirus that emerged in late 2019 has a single-strand, positive-sense RNA genome.
PCR is a molecular biology tool that is used to amplify a gene segment from a very small sample of DNA. Many millions of copies are produced, which allows the gene sequence of interest to be studied further.
The first step involves transforming the RNA into DNA using an enzyme called reverse transcriptase. A small amount of DNA is amplified into larger quantities which will be more easily detected. In a standard PCR, the lab technician can only find out the result of the test once it is complete. In a real-time PCR, a camera or detector can watch as the reaction takes place and give real-time feedback on how the test is going.
The waiting period the time you have to wait to get your results may be due to a number of factors all of which contribute to the reliability of your test result. The crucial one is to reduce the risk of getting a false negative (when the PCR test says you dont have the infection, but in fact you do).
According to the NICD, a false negative could occur when the specimen:
Technical reasons inherent in the test, for example virus mutation, may also lead to a false result.
False positives occur less often and may be the result of the slightest of contaminations in the testing process, among other factors.
The World Health Organisation, the Centers for Disease Control and Prevention, and the NICD provide guidance for laboratory testing on their websites. But the Covid-19 virus is new, so testing protocols are being formulated and refined as new knowledge emerges.
Other tests needed
At present, PCR tests can only be done in specialised laboratories. Even putting aside the time it takes to get the sample from the patient to the lab, the fastest available process takes at least four hours to get a result. This time includes the sample preparation and the actual analysis.
The backlog that is building up because of the increased demand for tests could mean the process will, in the short term, probably become slower rather than faster.
Other, quicker, types of tests are needed.
The US Food and Drug Administration (FDA) has in the past few days approved a test developed by molecular diagnostics company Cepheid. It produces a machine called the Gene Xpert, the size of a desktop computer, which can be used in health facilities to do PCR tests for the new coronavirus.
But at this stage it is unclear how well the Cepheid test works, how quickly the company can produce the reagents needed for it, what these will cost and how quickly it can be rolled out across the world.
To permit the use of this test, the FDA, on 29 February, posted new rules allowing emergency use authorisations of coronavirus tests other than the ones made and distributed by the US Centers for Disease Control and Prevention.
The RT-PCR test is recommended by the World Health Organisation.
Another possible way for testing would be that recommended by David Ho, a viral epidemic expert, who suggested antibody testing in his interview with Caltech.
To fight viruses, your body will begin producing antibodies. An antibody is a protective protein produced by your immune system to help it fight this foreign substance. These are usually cheaper and quicker than PCR tests, and can be done at a clinic quickly, with a patient able to get his result before going home.
Reports are emerging of promising antibody tests, but at the time of publication none had been approved. Things are changing quickly, however. For example, on 18 March 2020, researchers posted a preprint on the Medriv website of a serology test which would identify the antibodies within three days of the onset of symptoms. A serology test is a blood test that looks for antibodies in your blood.
The researchers were clear that this was not a clinical trial, but the first development towards such a test.
On March 22, the WHO published its interim guidance for Laboratory testing strategy recommendations for Covid-19. It stipulated that serological assays will play an important role in research and surveillance, but are not recommended for case detection at present.
The role of rapid disposable tests for antigen detection for Covid-19 needs to be evaluated and is not currently recommended for clinical diagnosis pending more evidence on test performance and operational utility.
Behind the scenes
There is a lot more going on behind the scenes in the testing lab than most people realise. Entire teams are working to ensure your results are reliable.
The process, by its very nature, is painstaking and methodical.
But the good news is that throughout the world, scientists are working together, sharing knowledge that is being accrued by the day. Theyre making tests that are quicker, and more reliable.
For informed information on how to proceed for testing, contact the National Institute for Communicable Diseases on its 24-hour toll-free number: 0800 029 999. DM
Fatima Khan has a background in laboratory research and education. She is currently enrolled on Roving Reporters environmental journalism training project. Additional reporting by GroundUp.
Please note you must be a Maverick Insider to comment. Sign up here or if you are already an Insider.
See original here:
Covid-19: Why testing takes time and what to expect - Daily Maverick
- Children's National Medical Center and AWS partner for genome project targeting COVID-19 - SiliconANGLE - July 6th, 2020
- Duke researchers help discover new strain of coronavirus that spreads faster because of gene mutation - WGHP FOX 8 Greensboro - July 6th, 2020
- Phenotype and Molecular Detection of Clarithromycin and Levofloxacin R | IDR - Dove Medical Press - July 6th, 2020
- EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer - Business Wire - July 6th, 2020
- Matteo Adinolfi obituary | From the Guardian - The Guardian - July 6th, 2020
- Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2... - July 6th, 2020
- Bing and Ol' Medicine Hat - Todayville.com - July 6th, 2020
- Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in se... - July 4th, 2020
- Movers & Shakers, July 3 | BioSpace - BioSpace - July 4th, 2020
- IHS Pets: Bringing Cell And Gene Therapy To Cats, Dogs & Horses - Anti Aging News - July 4th, 2020
- The Future of Medicine Is Bespoke - Fair Observer - July 4th, 2020
- Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer - GlobeNewswire - July 4th, 2020
- Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise - July 4th, 2020
- Eliminating the Long, Cumbersome and Costly Diagnosis of Genetic Diseases - HIT Consultant - July 4th, 2020
- Rare Disease Diagnostics Industry Anticipated to Reach $26.7 Billion by 2024 - Market Shares by Disease Class, Indication, Analysis Platform, Analysis... - July 4th, 2020
- 28 cool health things that started with a Canadian - Regina Leader-Post - July 4th, 2020
- Pools in the Mexican desert are a window into Earth's early life - Science Magazine - July 4th, 2020
- Personalized Cancer Drugs Market Expected to Witness a Sustainable Growth over 2025 - 3rd Watch News - July 4th, 2020
- Genetic Medicine will be the Solution to COVID-19, and Ligandal is Leading the way - PR Web - June 20th, 2020
- Sarepta Therapeutics and Selecta Biosciences Enter into Research License and Option Agreement for Selecta's ImmTOR Immune Tolerance Platform in... - June 20th, 2020
- Researchers identify environmental components that affect gene expression in cardiovascular disease - The South End - June 20th, 2020
- FDA officials update on orphan drugs, gene therapies at DIA - Regulatory Focus - June 20th, 2020
- Cell and gene therapy-focused OpenCell Technologies hires MilliporeSigma executive Kevin Gutshall as new CEO - PRNewswire - June 20th, 2020
- Pfizer and Sangamo report positive data from hemophilia A therapy trial - Clinical Trials Arena - June 20th, 2020
- Regenerative Medicine Market to Record a Robust Growth Rate for the COVID-19 Period - Cole of Duty - June 20th, 2020
- UCLA receives nearly $14 million from NIH to investigate gene therapy to combat HIV - UCLA Newsroom - June 20th, 2020
- 15 Biotech Companies In Houston To Know - Built In - June 20th, 2020
- Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome - BioSpace - June 20th, 2020
- Global Precision Medicine Market Growth From 2019 to 2025- Market Report, Insights Analysis And Opportunities - Cole of Duty - June 20th, 2020
- Obesity in mice prevented by disabling gene - Medical News Today - May 24th, 2020
- COVID-19 study looks at genetics of healthy people who develop severe illness - Washington University School of Medicine in St. Louis - May 24th, 2020
- UBC scientist identifies a gene that controls thinness - UBC Faculty of Medicine - UBC Faculty of Medicine - May 24th, 2020
- IU team pursuing breathtaking advancements in regenerative medicine - The Republic - May 24th, 2020
- Complement genes add to sex-based vulnerability in lupus and schizophrenia - UAB News - May 24th, 2020
- COVID-19-Related Genes Have Higher Expression in Certain Patients With Asthma - Pulmonology Advisor - May 24th, 2020
- Precision Medicine Informs Cost-Effective Heart Disease Treatments - HealthITAnalytics.com - May 24th, 2020
- Here's Why Editas Could Beat Intellia to a CRISPR Therapy - Motley Fool - May 24th, 2020
- FDA Approves Genentech's Tecentriq as a First-Line Monotherapy for Certain People With Metastatic Non-Small Cell Lung Cancer - Business Wire - May 24th, 2020
- Doctors race to understand rare inflammatory condition associated with coronavirus in young people - Science Magazine - May 24th, 2020
- Retinoic acid synthesis by ALDH1A proteins is dispensable for meiosis initiation in the mouse fetal ovary - Science Advances - May 24th, 2020
- COVID-19 UPDATE: Precision Medicine Market 2020: Industry Analysis and Detailed Profiles of Top Industry Players are Neon Therapeutics, Moderna, Inc,... - May 24th, 2020
- A Coronavirus Vaccine Candidate In Six Days? This Company Is Fast-Tracking Vaccine Development With The First Fully Automated Gene Synthesis Platform... - May 24th, 2020
- IU team pursues breathtaking regenerative medicine advances - The Advocate - May 17th, 2020
- Precision medicine guides choice of better drug therapy in severe heart disease - Science Codex - May 17th, 2020
- Sarepta Therapeutics' (SRPT) "Buy" Rating Reiterated at Robert W. Baird - MarketBeat - May 17th, 2020
- Gene Editing Technologies in Diagnostic Platforms Market is expected to grow at a CAGR of 14.4% during the forecast period due to the rise in research... - May 17th, 2020
- Akouos to Present Data from Inner Ear Gene Therapy Platform at 23rd ASGCT Annual Meeting - Business Wire - May 14th, 2020
- Sarepta Therapeutics and Dyno Therapeutics Announce Agreement to Develop Next-Generation Gene Therapy Vectors for Muscle Diseases - GlobeNewswire - May 14th, 2020
- Gene therapy in mice builds muscle, reduces fat Washington University School of Medicine in St. Louis - Washington University School of Medicine in... - May 14th, 2020
- New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European... - May 14th, 2020
- Gene therapy drug for infants priced at 170 million yen : The Asahi Shimbun - Asahi Shimbun - May 14th, 2020
- CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001 for the... - May 14th, 2020
- Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital... - May 14th, 2020
- bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25th European Hematology Association Annual... - May 14th, 2020
- Foundation Medicine and Collaborators to Share New Data During the ASCO20 Virtual Scientific Program Showcasing the Importance of Comprehensive... - May 14th, 2020
- Researchers: Disease affecting kids could be in the genes - Newsday - May 14th, 2020
- Tech optimization: Unlocking the promise of precision medicine - Healthcare IT News - May 14th, 2020
- FDA Approves RET Inhibitor Retevmo for Lung and Thyroid Cancer - Cancer Health Treatment News - May 14th, 2020
- The Cell Therapy Industry to 2028: Global Market & Technology Analysis, Company Profiles of 309 Players (170 Involved in Stem Cells) -... - May 14th, 2020
- INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12... - May 14th, 2020
- 21-Gene Recurrence Scores of 26 or Higher Can Help Determine If Chemotherapy Will Be Effective - MedicalResearch.com - May 14th, 2020
- Obesity prevented in mice treated with gene-disabling nanoparticles - Washington University School of Medicine in St. Louis - May 1st, 2020
- Optics makes amazing things possible in biological research and medicineand Optikos makes it happen - Mass Device - May 1st, 2020
- Drug-gene testing could give experts insight into COVID-19 treatment - ModernHealthcare.com - May 1st, 2020
- What Do Your Genetics Have to Do With Your Chances of Dying From Coronavirus? - Vanity Fair - May 1st, 2020
- Vertex Receives European CHMP Positive Opinion for KALYDECO (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months... - May 1st, 2020
- Val Sheffield elected to the American Academy of Arts and Sciences - Iowa Now - May 1st, 2020
- Sarepta Therapeutics to Announce First Quarter 2020 Financial Results and Recent Corporate Developments on May 6, 2020 - GlobeNewswire - May 1st, 2020
- Mechanistic Similarities between 3D Human Bronchial Epithelium and Mice Lung, Exposed to Copper Oxide Nanoparticles, Support Non-Animal Methods for... - May 1st, 2020
- PGDx received FDA clearance for its genomic cancer diagnostic kit. It's the first for a test of its kind - Technical.ly - May 1st, 2020
- Bayer and OrigiMed reached a partnership to develop a next generation sequencing (NGS) based companion diagnostic-in vitro diagnostic (CDx-IVD)... - May 1st, 2020
- More Than Meets the Eye: Veterinary Ophthalmologist Wendy Townsend Focuses on Animal Eye Conditions - Purdue Veterinary News - May 1st, 2020
- COVID-19: What's RNA research got to do with it? - University of Rochester - May 1st, 2020
- New Data For Teva AJOVY (fremanezumab-vfrm) Injection and AUSTEDO (deutetrabenazine) Tablets Included in Neurology - BioSpace - May 1st, 2020
- Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes |... - May 1st, 2020
- Evotec Expands into Gene Therapy - Associated Press - April 6th, 2020
- Siddhartha Mukherjee and Ken Burns Present PBS Premiere of 'The Gene: An Intimate History' - Columbia University - April 6th, 2020
- How 'viral load' and genetics could explain why young people have died from coronavirus - The Independent - April 6th, 2020
- BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe... - April 6th, 2020
- What The Coronavirus Does To Your Body That Makes It So Deadly - IFLScience - April 6th, 2020